This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...
PharmaJet plans to expand their needle-free injection portfolio with a suite of proprietary, needle-free, self-injector pens.
Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors. In an interview with CURE®, Dr. Eric K.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...
The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.
Zepbound is a prescription injectable medication that’s used for weight loss. You or a caregiver can administer it as a subcutaneous injection into your stomach or thigh. A caregiver can also ...
SurvivorNet on MSN
FDA Approves New Subcutaneous (Under-the-Skin) Option for Keytruda: What It Means for Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...
Most people know the feeling of getting a shot and having your arm feel sore for several days afterward. Some might even expect it as a side effect. The soreness happens when medications are injected ...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Injection site reactions are the most common side effect of Emgality. The most frequent injection site reaction is pain. But there are steps you can take to help prevent or reduce pain from Emgality ...
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results